Hepatocellular carcinoma (HCC) is one of the deadliest malignant tumors in the world, and its incidence and mortality have increased year by year. HCC research has increasingly focused on ...

Iterion Therapeutics announced that two abstracts featuring its first-in-class TBL1 inhibitor, tegavivint, will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

A new study reveals why some pancreatic and colorectal tumors resist targeted anti-Wnt drugs and suggests how to overcome it, offering new hope to patients with fully treatment-resistant cancers.

Researchers from the Ottawa HospitalResearch Institute and the University of Ottawa in Canada, along with researchers from the Centre for Genomic Regulation at the Barcelona Institute for Science and ...

A pair of USC Stem Cell mouse studies detail how progenitor cells self-renew, differentiate, and aggregate into early kidney structures, offering insights for the creation of stem cell-based ...

A Wnt/β-catenin pathway agonist under development by Surrozen appears to be effective against idiopathic pulmonary fibrosis (IPF) in mouse models, according to new data. The results, published April 2 ...